Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 6/20 | 1.00 |
| ▸ | PAX8 | Q06710 | 4/20 | 1.00 |
| ▸ | LMNA | P02545 | 4/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 1.00 |
| ▸ | RAB9A | P51151 | 4/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 3/20 | 1.00 |
| ▸ | NPC1 | O15118 | 3/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 2/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 1.00 |
| ▸ | SLCO4C1 | Q6ZQN7 | 1/20 | 1.00 |
| ▸ | ATP1A1 | P05023 | 9/20 | 0.74 |
| ▸ | ATP1B1 | P05026 | 9/20 | 0.74 |
| ▸ | ATP1B2 | P14415 | 9/20 | 0.74 |
| ▸ | ATP1A2 | P50993 | 9/20 | 0.74 |
| ▸ | ATP1B3 | P54709 | 9/20 | 0.74 |
| ▸ | TSHR | P16473 | 2/20 | 0.74 |
| ▸ | ATP1A3 | P13637 | 2/20 | 0.74 |
| ▸ | FXYD2 | P54710 | 2/20 | 0.74 |
| ▸ | ATP1A4 | Q13733 | 2/20 | 0.74 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Digoxigenin SCHEMBL13337910 | 1.00 | TP53 (1.00) | TP53PAX8LMNASMN1; SMN2RAB9A | |
| Digoxigenin SCHEMBL8816469 | 1.00 | TP53 (1.00) | TP53PAX8LMNASMN1; SMN2RAB9A | |
| Digoxigenin SCHEMBL4994463 | 1.00 | TP53 (1.00) | TP53PAX8LMNASMN1; SMN2RAB9A | |
| Digoxigenin SCHEMBL21105 | 1.00 | TP53 (1.00) | TP53PAX8LMNASMN1; SMN2RAB9A | |
| Digoxigenin SCHEMBL24012132 | 1.00 | TP53 (1.00) | TP53PAX8LMNASMN1; SMN2RAB9A | |
| Digoxigenin SCHEMBL13362000 | 1.00 | TP53 (1.00) | TP53PAX8LMNASMN1; SMN2RAB9A | |
| Digoxigenin SCHEMBL23827178 | 1.00 | TP53 (1.00) | TP53PAX8LMNASMN1; SMN2RAB9A | |
| Digoxigenin SCHEMBL11077489 | 1.00 | TP53 (1.00) | TP53PAX8LMNASMN1; SMN2RAB9A | |
| Digoxigenin SCHEMBL8816474 | 1.00 | TP53 (1.00) | TP53PAX8LMNASMN1; SMN2RAB9A | |
| Digoxigenin SCHEMBL29477343 | 1.00 | TP53 (1.00) | TP53PAX8LMNASMN1; SMN2RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11730746-B2 | 17beta-heterocyclyl-digitalis like compounds for the treatment of heart failure | CVIE THERAPEUTICS LIMITED (TW) | 2023-08-22 | — | — | US | disclosed |
| US-11730746-B2 | 17beta-heterocyclyl-digitalis like compounds for the treatment of heart failure | CVIE THERAPEUTICS LIMITED (TW) | 2023-08-22 | — | — | US | disclosed |
| US-20210283147-A1 | 17BETA-HETEROCYCLYL-DIGITALIS LIKE COMPOUNDS FOR THE TREATMENT OF HEART FAILURE | CVIE THERAPEUTICS LIMITED (TW) | 2021-09-16 | — | — | US | disclosed |
| WO-2020020728-A1 | 17BETA-HETEROCYCLYL-DIGITALIS LIKE COMPOUNDS FOR THE TREATMENT OF HEART FAILURE | UNIVERSITA' DEGLI STUDI DI MILANO-BICOCCA (IT) | 2020-01-30 | — | — | WO | disclosed |
| EP-3599243-A1 | 17BETA-HETEROCYCLYL-DIGITALIS LIKE COMPOUNDS FOR THE TREATMENT OF HEART FAILURE | CVIE Therapeutics Limited (TW) | 2020-01-29 | — | — | EP | disclosed |
| WO-2011036557-A1 | COMPOSITIONS AND METHODS FOR ENHANCING CELLULAR UPTAKE AND INTRACELLULAR DELIVERY OF LIPID PARTICLES | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2011-03-31 | — | — | WO | disclosed |
| WO-2010068247-A1 | CARDENOLIDES FOR THE TREATMENT OF OCULAR CANCER | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2010-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11730746-B2 | 17beta-heterocyclyl-digitalis like compounds for the treatment of heart failure | CYP8B1, CYP24A1, NPPA | TP53 4269/4885PAX8 376/4885LMNA 234/4885 |
| US-20210283147-A1 | 17BETA-HETEROCYCLYL-DIGITALIS LIKE COMPOUNDS FOR THE TREATMENT OF HEART FAILURE | CYP8B1, CYP24A1, NPPA | TP53 4269/4885PAX8 376/4885LMNA 234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.